DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Sachetta LLC

Sachetta LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 255.2% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 238 shares of the medical device company’s stock after buying an additional 171 shares during the quarter. Sachetta LLC’s holdings in DexCom were worth $27,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom during the second quarter valued at $25,000. DSM Capital Partners LLC acquired a new stake in shares of DexCom during the 4th quarter valued at about $28,000. Crewe Advisors LLC purchased a new position in shares of DexCom in the 1st quarter valued at about $29,000. Riverview Trust Co acquired a new position in DexCom in the 1st quarter worth about $32,000. Finally, DT Investment Partners LLC boosted its position in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Down 1.7 %

Shares of DXCM opened at $68.55 on Wednesday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The stock has a fifty day simple moving average of $84.93 and a two-hundred day simple moving average of $112.21. The company has a market capitalization of $27.47 billion, a PE ratio of 44.23, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.34 earnings per share. As a group, equities analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Activity

In related news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at $7,646,115.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,311 shares of company stock valued at $234,214. 0.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DXCM. Canaccord Genuity Group restated a “buy” rating and issued a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. BTIG Research decreased their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Morgan Stanley dropped their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. Oppenheimer reduced their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Finally, Barclays lowered their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.